肿瘤细胞治疗研究
英文原题：New Immunotherapy Combinations Enter the Battlefield of Malignant Mesothelioma.
靶向间皮素的嵌合抗原受体（CAR）T细胞联合pembrolizumab，以及atezolizumab联合bevacizumab，近期在恶性胸膜和腹膜间皮瘤的I期试验中显示出临床疗效。
靶向间皮素的嵌合抗原受体（CAR）T细胞联合pembrolizumab，以及atezolizumab联合bevacizumab，近期在恶性胸膜和腹膜间皮瘤的I期试验中显示出临床疗效。尽管受试人群经过高度筛选，且需要难以放大的复杂工程化改造，CAR T细胞联合pembrolizumab仍首次为基因组异质性低的冷肿瘤带来了疗效证据，而atezolizumab-bevacizumab则为一种孤儿病提供了易于使用的抗血管生成联合免疫治疗。参见Raghav等人的相关文章，第2738页。参见Adusumilli等人的相关文章，第2748页。
Chimeric antigen receptor (CAR) T cells targeting mesothelin plus pembrolizumab, and atezolizumab plus bevacizumab, have recently shown clinical efficacy in phase I trials in malignant pleural and peritoneal mesothelioma. Despite being tested in a highly selected patient population and requiring a complex engineering that can hardly be upscaled, CAR T cells combined with pembrolizumab bring the first proof of efficacy in cold solid tumors with low genomic heterogeneity, while atezolizumab-bevacizumab offers an easy-to-use combination of antiangiogenics and immunotherapy in an orphan disease. See related article by Raghav et al., p. 2738 . See related article by Adusumilli et al., p. 2748 .
MEMBER ACCOUNT
登录成功会直接打开下一页。
